The Indianapolis-based drugmaker finally won FDA approval for its antidepressant Cymbalta to treat chronic pain and fended off a patent challenge to rising-star cancer drug Alimta, but got a ratings downgrade on its debt.
Could nurse practitioners get a promotion in the medical field? At least one health insurer is treating them like doctors now.
Eli Lilly and Co.’s $800 million acquisition of Avid Radiopharmaceuticals Inc. is the biggest step yet in the drugmaker’s attempt to add diagnostics to its product portfolio.
Eli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients with Alzheimer’s disease. The price could climb to $800 million if the agent is commercially successful.
In Utah, employers can give each of their workers a specific amount of money to apply toward health insurance. The worker then can use that money to choose from the 66 plans in the health insurance exchange.
New recruiter compensation rules adopted by the U.S. Department of Education could be one more thing that slows or even reverses the torrid growth of Carmel-based ITT Educational Services Inc.
Red tape involved in firing teachers is thick. But risk-averse administrators may be the bigger problem.
The Indianapolis-based health insurer raised its full-year profit forecast by 20 cents per share, after lower-than-expected claims and lower administrative costs increased third-quarter profit by 1 percent.
Jim Hamilton, an employee-benefits lawyer at Bose McKinney & Evans in Indianapolis, discussed the likelihood of a Republican-controlled U.S. House of Representatives changing or even outright repealing the health care reform law, formally known as the Patient Protection and Affordable Care Act.
Excluding investment and special charges, the Carmel-based life and health insurer on Tuesday reported a profit $47.1 million, down 13 percent from the same quarter a year ago, but still beat analysts’ expectations.
After recently deciding to close a research center in Singapore, Indianapolis-based Eli Lilly and Co. has decided to open a diabetes research center in China in the second half of 2011, further ramping up the drugmaker’s presence in the world’s fastest-growing pharmaceutical market.
Local leaders are encouraging The Oaks Academy to duplicate its successful urban private school model at a second location as part of the massive investment in near-east-side redevelopment spurred on by Indianapolis’ successful bid for the 2012 Super Bowl.
Eli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs in back-to-back years.
Dijuana Lewis will get nearly $3.2 million on her way out the door at WellPoint Inc. after what sources described as a dispute with CEO Angela Braly over a change in duties.
Indiana University will no longer ask employees to fill out an online health risk assessment after more than 550 people—many anonymous—attached names to an online petition that said the plan would cause “widespread anger and disillusionment.”
Wall Street analysts on Thursday demanded to know what new things Eli Lilly and Co. is planning since the company’s vaunted pipeline has failed to produce a drug that will boost revenue after a wave of patent expirations. The answer: Not much.
ITT Educational Services Inc.’s third-quarter profit of $93.2 million handily beat the expectations of Wall Street analysts, but the company suffered its first decline in new-student enrollment since the recession began.
The Indianapolis-based drugmaker reported a profit of $1.3 billion in the quarter ended Sept. 30, up 38 percent compared with last year. Excluding extraordinary items from a year ago, Lilly’s profit was up 2 percent.
The Carmel-based for-profit educator stands to suffer a bigger impact than its peers from new regulations proposed by the U.S. Department of Education, which have already forced the industry behemoth to slash its forecasts.
Eli Lilly and Co. will have to wait at least 18 months and conduct more studies before it wins market approval of a once-weekly version of diabetes drug Byetta, a potential billion-dollar drug.
